Nuveen LLC Buys New Stake in Perspective Therapeutics, Inc. $CATX

Key Points

• Nuveen LLC acquired a new stake in Perspective Therapeutics, Inc. with 1,242,542 shares valued at approximately $2.65 million, representing a 1.68% ownership in the company.
• Several institutional investors increased their stakes in Perspective Therapeutics during the fourth quarter, contributing to a total of 54.66% ownership by hedge funds and institutional investors.
• Brokerages have positive outlooks on the stock, with most analysts giving it a "Buy" rating and setting an average price target of $12.56, reflecting confidence in its growth potential.

Nuveen LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,242,542 shares of the company's stock, valued at approximately $2,647,000. Nuveen LLC owned approximately 1.68% of Perspective Therapeutics as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C lifted its position in Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company's stock worth $9,375,000 after buying an additional 120,991 shares during the period. Octagon Capital Advisors LP increased its stake in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after acquiring an additional 882,528 shares during the last quarter. Millennium Management LLC acquired a new stake in Perspective Therapeutics during the fourth quarter worth about $4,132,000. Two Sigma Investments LP acquired a new stake in Perspective Therapeutics during the fourth quarter worth about $2,075,000. Finally, Velan Capital Investment Management LP acquired a new stake in Perspective Therapeutics during the fourth quarter worth about $1,595,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on CATX shares. B. Riley restated a "buy" rating and set a $12.00 price target (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Royal Bank Of Canada upgraded Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and upped their price target for the stock from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Saturday, July 12th. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, Truist Financial lowered their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Trading Down 0.6%

CATX traded down $0.02 on Friday, reaching $3.36. The company's stock had a trading volume of 456,073 shares, compared to its average volume of 927,790. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.31. The business's 50 day moving average is $3.79 and its 200 day moving average is $2.97.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.